PHARMOCANN GLOBAL LTD |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 240 ILa | 0.00% |
|
0.00% | +71.31% |
| Apr. 16 | Pharmocann Global Ltd announced that it has received ILS 0.15554 million in funding | CI |
| Mar. 31 | Pharmocann Global Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | 22.66M 6.06M 2.27B | Sales 2023 | 14.41M 3.86M 1.44B | Capitalization | 3.12M 835K 312M |
|---|---|---|---|---|---|
| Net income 2022 | -25M -6.69M -2.5B | Net income 2023 | -9M -2.41M -900M | EV / Sales 2022 | 0.4 x |
| Net cash position 2022 | 925K 247K 92.5M | Net cash position 2023 | 768K 205K 76.8M | EV / Sales 2023 | 0.16 x |
| P/E ratio 2022 |
-0.26
x | P/E ratio 2023 |
-0.28
x | Employees | 14 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 53.18% |
More Fundamentals
* Assessed data
More news
| 1 month | -39.30% | ||
| 3 months | +45.10% | ||
| 6 months | +54.94% | ||
| Current year | +71.31% |
1 week
240.00
240.00
1 month
240.00350.00
Current year
51.10400.00
1 year
51.10400.00
3 years
51.1015 400.00
5 years
51.1030 900.00
10 years
51.1036 990.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 40 | 19-06-16 | |
Daniel Spira
AUD | Comptroller/Controller/Auditor | 70 | 19-12-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Guy Sigura
CHM | Chairman | 47 | 22-12-04 |
Locar Gila
BRD | Director/Board Member | 51 | 22-11-28 |
| Director/Board Member | 43 | 22-11-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-02 | 240 | 0.00% | 400 |
| 24-07-01 | 240 | 0.00% | 6 |
| 24-06-25 | 240 | 0.00% | 948 |
Delayed Quote TEL AVIV STOCK EXCHANGE, July 03, 2024 at 10:24 am EDT
More quotes
Medical Compression System DBN Ltd is an Israel-based company active in the medical sector. It is engaged in the research, development, production and marketing of non-invasive and non-medicinal solutions to improve the blood flow processes, using a pneumatic device which places pressure on the limbs by means of compressed air. The technology developed by the Company facilitates reducing the risk of blood clots forming during traumatic and surgical events, and secular diseases. It also completed the development of a pneumatic device for preventing the formation of blood clots in the deep veins system as the result of a trauma or surgical intervention, which is called the ActiveCare DVT.
| 1st Jan change | Capi. | |
|---|---|---|
| +71.31% | 1.63M | |
| +7.41% | 217M | |
| -12.37% | 181M | |
| +24.42% | 163M | |
| +300.00% | 121M | |
| +26.02% | 114M | |
| -28.57% | 121M | |
| +75.79% | 94.67M | |
| -58.78% | 87.06M | |
| -15.38% | 73.86M |
- Stock Market
- Equities
- PMCN-M Stock
